ERBB2 and neoplasm: The results suggested a significant improvement of tumor reduction when once daily (QD) and/or twice daily (BID) schedules were considered, especially in the HER2+ cell line since tumor eradication is predicted at 1 mg/kg BID and 10 mg/kg BID or QD.